Though the Conrad's false mussel, Mytilopsis leucophaeata, is an important fouling animal in industrial cooling water systems, there are no published reports on the tolerance of this species to chlorination. A series of experiments was conducted to determine the effects of mussel size (2-20 mm shell length), season (breeding versus nonbreeding), nutritional status (fed versus starved) and acclimation temperature (5-30 degrees C) on the mortality pattern of M. leucophaeata under continuous chlorination (0.25-5 mg/L). The effect of mussel size on M. leucophaeata mortality in the presence of chlorine was significant, with 10 mm size group mussels showing greater resistance. At 0.25 mg/L residual chlorine, 2 mm size group mussels took 89 days to reach 100% mortality, whereas 10 mm size group mussels took 109 days. M. leucophaeata collected during nonbreeding season (December-April) was more tolerant to chlorine than those collected during breeding season (June-October). Nutritional status of the mussel had no significant influence on the chlorine tolerance of the mussel: fed and starved mussels succumbed to chlorine at equal rates. The effect of acclimation temperature on M. leucophaeata mortality in the presence of chlorine was significant. At 0.5 mg/L residual chlorine, mussels acclimated at 5 degrees C required 99 days to reach 95% mortality, whereas mussels acclimated at 30 degrees C required 47 days. A comparison of present data with previous reports suggests that resistance of M. leucophaeata to chlorination is higher than other mussel species causing fouling problems in The Netherlands ( Mytilus edulis and Dreissena polymorpha).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00244-002-1203-6 | DOI Listing |
Background: Clinical trial sponsors rely on research sites to identify and enroll appropriate study participants and to correctly and reliably assess symptom severity and function over the course of the trial. Low-recruiting sites represent a large financial and operational burden and may negatively impact trial success either by selecting inappropriate participants and/or high prevalence of data quality issues. We previously reported that >60% of sites in schizophrenia clinical trials recruited ≤5 participants.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Washington University School of Medicine, St. Louis, MO, USA.
Background: The well-accepted statistical efficacy inference approach for Alzheimer's disease (AD) clinical trials compares the absolute difference in change from baseline at the last study visit using MMRM (henceforth referred to as MMRM-Last-Visit). Recent AD clinical trials have shown that treatment effects may be manifested prior to 18 months. The objective is to evaluate models estimating an overall treatment effect across all post-baseline visits that may characterize disease modifying effects in contemporary early AD clinical trials.
View Article and Find Full Text PDFBackground: Abnormal glucose metabolism in AD brains correlates with cognitive deficits. The glucose changes are consistent with brain thiamine (vitamin B1) deficiency. In animals, thiamine deficiency causes multiple AD-like changes including memory loss, neuron loss, brain inflammation, enhanced phosphorylation of tau, exaggerated plaque formation and elevated advanced glycation end products (AGE).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Clinical trials should strive to yield results that are clinically meaningful rather than solely relying on statistical significance. However, the determination of clinical meaningfulness of dementia clinical trials lacks standardization and varies based on the trial's nature. To tackle this issue, a proposed approach involves assessing the time saved before reaching a specific threshold in cognitive status.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Applied Medical Sciences, Misr University for Science and Technology, Cairo, Egypt.
Background: Gamma desynchronization is an early pathophysiological event in Alzheimer's disease with a disturbance in oscillation in the gamma frequency range 30-80 Hz. This disruption was found to be directly related to the disease progression and severity. Thus, the use of transcranial alternating current stimulation (tACS) possessed greater interest.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!